Table 1.
Clinical and Physiological Characteristics of Culture-Positive Infected and Noninfected Acetaminophen Acute Liver Failure Patients
| Parameter | Infected AALF | Noninfected AALF |
|---|---|---|
| Patients, n | 11 | 24 |
| Age, y | 31.00 (27.00−49.00) | 36.00 (27.00−48.00) |
| WBC, ×109/L | 6.700 (5.910−8.130) | 8.710 (5.925−11.61) |
| Monocytes, ×109/L | 0.2000 (0.1300−0.2600) | 0.3200 (0.1250−0.6050) |
| Lymphocytes, ×109/L | 0.5100 (0.3000−0.7400) | 0.7400 (0.3200−1.105) |
| SIRS score | 3.000 (2.000−4.000) | 3.000 (2.000−4.000) |
| MELD score | 39.00 (37.00−43.00) | 39.00 (31.00−41.00) |
| Bilirubin, μmol/L | 70.00 (44.00−140.0) | 90.00 (69.00−162.0) |
| INR | 4.040 (2.870−6.250) | 4.480 (2.480−6.340) |
| Creatinine, μmol/L | 259.0 (90.00−360.0) | 93.00 (63.00−239.5) |
| Urea, mmol/L | 11.30 (5.700−14.00) | 7.000 (4.900−8.700) |
| AST, IU/mL | 4703a (2521−8861) | 1665 (951.5−3756) |
| Ammonia, μmol/L | 87.50 (54.75−138.5) | 99.00 (67.50−150.3) |
| Encephalopathy score | 3.000b (3.000−4.000) | 2.000 (1.000−3.000) |
| CTLA4, % | 3.005b (0.8575−6.418) | 1.200 (0.6750−3.015) |
| Outcomes,c n | ||
| OLT | 2 | 8 |
| Survivors | 6 | 16 |
| Nonsurvivors | 3 | 0 |
NOTE. Values are median (IQR) unless otherwise noted.
ALD, acute liver disease; AST, aspartate aminotransferase; INR, international normalized ratio; MELD, Model for End-Stage Liver Disease; OLT, orthotopic liver transplantation; NA, not applicable; ND, not determined; SIRS, systemic inflammatory response syndrome criteria score.
a
P = .01.
b
P < .002, compared to noninfected.
c
Outcomes at 28 days post admission.